| NCT05214482 |
Akeso |
AK117 (ligufalimad) |
anti-CD47 |
Advanced Malignant Tumors |
AK112 (bispecific PD-1+VEGF Ab) + AK117 + chemotherapy |
I |
Ongoing |
| NCT05229497 |
Akeso |
AK117 (ligufalimad) |
anti-CD47/EGFR |
Advanced Malignant Tumors |
AK117 + AK112 |
Ib/II |
Unknown |
| NCT05235542 |
Akeso |
AK117 (ligufalimad) |
anti-CD47/EGFR |
Advanced Malignant Tumors |
AK117 + AK104 |
Ib/II |
Unknown |
| NCT05960955 |
Akeso |
AK117 (ligufalimad) |
anti-CD47/EGFR |
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma |
AK117 + Cadonilimab |
II |
Recruiting |
| NCT06508606 |
Akeso Bio |
AK117 (ligufalimad) |
anti-CD47/EGFR |
metastatic head and neck squamous cell carcinoma |
Standard of Care |
II |
Not Yet Recruiting |
| NCT06387420 |
Akeso Bio |
AK117 (ligufalimad) |
anti-CD47/EGFR |
Acute Myeloid Leukemia |
AK117 + Azacitidine + Venetoclax |
Ib/II |
Not Yet Recruiting |
| NCT06642792 |
Akeso Bio |
AK117 (ligufalimad) |
anti-CD47/EGFR |
Hodgkin lymphoma |
AK117 + AK129 |
I/II |
Recruiting |
| NCT04900350 |
Akeso Bio |
AK117 (ligufalimad) |
anti-CD47/EGFR |
Higher Risk Myelodysplastic Syndrome |
AK117 + azacitidine |
I/II |
Ongoing |
| NCT04980885 |
Akeso Bio |
AK117 (ligufalimad) |
anti-CD47/EGFR |
Acute Myeloid Leukemia |
AK117 + azacitidine |
Ib/II |
Ongoing |
| NCT06166472 |
Akeso Bio |
AK132 |
anti-CD47/CLDN18.2 bifunctional Ab |
Advanced Malignant Solid Tumor |
Standard of Care |
I |
Not Yet Recruiting |
| NCT05524545 |
ALX Oncology |
ALX148 (evorpacept) |
Fc-SIRPalpha hybrid |
Bladder Cance Urothelial Carcinoma |
ALX148 + pembrolizumab |
I |
Ongoing |
| NCT03013218 |
ALX Oncology |
ALX148 (evorpacept) |
Fc-SIRPalpha hybrid |
Advanced solid tumors and lymphoma |
Standard of Care |
I |
Ongoing |
| NCT07007559 |
ALX Oncology |
ALX148 (evorpacept) |
Fc-SIRPalpha hybrid |
Advanced / Metastatic Malignancies |
Standard of Care |
I/II |
Recruiting |
| NCT04675333 |
ALX Oncology |
ALX148 (evorpacept) |
Fc-SIRPalpha hybrid |
Advanced Head and Neck Squamous Cell Carcinoma |
ALX148 + pembrolizumab + Cisplatin/Carboplatin + 5FU |
II |
Ongoing |
| NCT04675294 |
ALX Oncology |
ALX148 (evorpacept) |
Fc-SIRPalpha hybrid |
Advanced Head and Neck Squamous Cell Carcinoma |
ALX148 + pembrolizumab |
II |
Ongoing |
| NCT05002127 |
ALX Oncology |
ALX148 (evorpacept) |
Fc-SIRPalpha hybrid |
Advanced HER2+ Gastric Cancer |
Standard of Care |
II/III |
Ongoing |
| NCT05025800 |
ALX Oncology, M.D. Anderson Cancer Center |
ALX148 (evorpacept) |
Fc-SIRPalpha hybrid |
B-cell non-Hodgkin lymphoma |
ALX148 + rituximab + lenalidomide |
I/II |
Ongoing |
| NCT05467670 |
ALX Oncology, Merck Sharp & Dohme LLC |
ALX148 (evorpacept) |
Fc-SIRPalpha hybrid |
Recurrent Platinum-resistant Ovarian Cancer |
Pembrolizumab (Keytruda) + ALX148 + Doxorubicin |
II |
Recruiting |
| NCT04417517 |
ALX Oncology, Merck Sharp & Dohme LLC |
ALX148 (evorpacept) |
Fc-SIRPalpha hybrid |
Higher Risk Myelodysplastic Syndrome |
ALX148 + azacitidine |
I/II |
Ongoing |
| NCT05167409 |
University of Colorado, Denver |
ALX148 (evorpacept) |
Fc-SIRPalpha hybrid |
Refractory Microsatellite Stable Metastatic Colorectal Cancer |
ALX148 + Cetuximab + Pembrolizumab |
II |
Ongoing |
| NCT05607199 |
Aurigene |
AUR103 |
CD47 Small Molecule |
Solid Tumor Acute Myeloid Leukemia Myelodysplastic Syndromes Non Hodgkin Lymphoma |
Standard of Care |
I |
Recruiting |
| NCT05767060 |
Bio-Thera Solutions |
BAT7104 |
anti-PDL1/CD47 bifunctional Ab |
Advanced Malignant Tumor |
Standard of Care |
I |
Recruiting |
| NCT06932952 |
Byondis B.V. |
BYON4228 |
anti-SIRPalpha |
Solid tumors |
BYON4228 + Pembrolizumab |
I |
Not Yet Recruiting |
| NCT05737628 |
Byondis B.V. |
BYON4228 |
anti-SIRPalpha |
Lymphoma |
BYON4228 + Rituximab |
I |
Recruiting |
| NCT05957536 |
D3 Bio (Wuxi) Co., Ltd |
D3L-001 |
anti-CD47/HER2 bifunctional Ab |
HER2-Positive Advanced Solid Tumors |
Standard of Care |
I |
Recruiting |
| NCT05765851 |
Daiichi Sankyo |
DS-1103a |
anti-SIRPalpha |
Advanced Solid Tumors |
Standard of Care |
I |
Ongoing |
| NCT05263271 |
Changchun GeneScience Pharmaceutical Co., Ltd. |
Gentulizumab |
anti-CD47 |
Relapsed/Refractory Acute Myelogenous Leukemia/Myelodysplastic Syndrome |
Standard of Care |
I |
Recruiting |
| NCT06487624 |
FBD Biologics Limited |
HCB301 |
anti-PD-L1/SIRPα/TGF-β |
Hodgkin lymphoma |
Standard of Care |
I |
Recruiting |
| NCT05189093 |
Hangzhou Hanx Biopharmaceuticals, Ltd. |
HX009 |
anti-CD47/PD-1 bifunctional Ab |
Relapsed/Refractory Lymphoma |
Standard of Care |
I/II |
Recruiting |
| NCT05731752 |
Hangzhou Hanx Biopharmaceuticals, Ltd. |
HX009 |
anti-CD47/PD-1 bifunctional Ab |
Advanced Solid Tumors |
Standard of Care |
I |
Ongoing |
| NCT04886271 |
Waterstone Hanxbio Pty Ltd |
HX009 |
anti-CD47/PD-1 bifunctional Ab |
advanced solid tumors |
Standard of Care |
II |
Unknown |
| NCT04980690 |
BioPharmaceutical CO., Ltd. |
IBC0966 |
anti-CD47/PD-L1 bifunctional Ab |
Advanced malignant tumors |
Standard of Care |
I/II |
Recruiting |
| NCT05276310 |
ImmuneOncia Therapeutics |
IMC-002 |
anti-CD47 |
Advanced cancers |
Standard of Care |
I |
Recruiting |
| NCT05771883 |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. |
IMM0306 |
anti-CD47/CD20 bifunctional Ab |
Relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma |
IMM0306 + Lenalidomide |
I/II |
Not Yet Recruiting |
| NCT05780307 |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. |
IMM2520 |
anti-CD47/PD-1 bifunctional Ab |
advanced solid tumors |
Standard of Care |
I |
Recruiting |
| NCT05805956 |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. |
IMM2902 |
anti-CD47/HER2 bifunctional Ab |
HER2-expressing advanced solid tumors |
Standard of Care |
I/II |
Unknown |
| NCT05615974 |
LaNova Medicines Limited |
LM-101 |
anti-SIRPalpha |
Advanced Malignant Tumors |
LM101 + Toripalimab + Rituximab |
I/II |
Recruiting |
| NCT04788043 |
Stanford University |
Magrolimab |
anti-CD47 |
Relapsed or Refractory Hodgkin Lymphoma |
Magrolimab + Pembrolizumab |
II |
Ongoing |
| NCT05896163 |
Pfizer |
Maplirpacept (TTI-622 or PF-07901801) |
anti-CD47 |
relapsed/refractory diffuse large B-cell lymphoma |
Maplirpacept + Glofitamab |
I/II |
Recruiting |
| NCT05403554 |
Light Chain Bioscience - Novimmune SA |
NI-1801 |
anti-CD47/Mesothelin bifunctional Ab |
Mesothelin Expressing Solid Cancers |
Standard of Care |
I |
Recruiting |
| NCT04881045 |
Pfizer |
PF-07257876 |
anti-CD47/PD-L1 bifunctional Ab |
Non-Small Cell Lung Cancer Squamous Cell Carcinoma of the Head and Neck Ovarian Cancer |
Standard of Care |
I |
Completed |
| NCT05652686 |
Phanes Tx & Roche |
PT217 (Peluntamig) |
anti-CD47/DLL3 |
Small Cell Lung Cancer (SCLC) Large Cell Neuroendocrine Cancer (LCNEC) Neuroendocrine Prostate Cancer (NEPC)|Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)|Neuroendocrine Carcinomas (NEC)|Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) |
PT217 + Carboplatin + Etoposide + Paclitaxel |
I/II |
Recruiting |
| NCT05482893 |
Phanes Therapeutics |
PT886 (Spevatamig) |
anti-CD47/CLDN18.2 bifunctional Ab |
Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas |
|
I/II |
Recruiting |
| NCT05857332 |
Hangzhou Sumgen Biotech Co., Ltd. |
SG1906 |
anti-CD47/CLDN18.2 bifunctional Ab |
CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors |
Standard of Care |
I |
Recruiting |
| NCT04900519 |
Sorento Therapeutics |
STI-6643 |
anti-CD47 |
Refractory Tumor |
Standard of Care |
I |
Unknown |
| NCT05192512 |
Chia Tai Tianqing Pharmaceutical Group & Nanjing Shunxin Pharmaceutical Co., Ltd. |
TQB2928 |
anti-CD47 |
Advanced cancers |
Standard of Care |
I |
Unknown |
| NCT06438783 |
Chia Tai Tianqing Pharmaceutical Group & Nanjing Shunxin Pharmaceutical Co., Ltd. |
TQB2928 |
anti-CD47 |
Metastatic Osteosarcoma and Other Solid Tumors |
TQB2928 + Anlotinib |
I |
Ongoing |
| NCT04854681 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
TQB2928 |
anti-CD47 |
Advanced Solid Tumors and Hematological Malignancies |
Standard of Care |
I |
Unknown |
| NCT06008405 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
TQB2928 |
anti-CD47 |
Acute Myeloid Leukemia Myelodysplastic Syndromes |
QB2928 + Azacitidine |
I |
Unknown |
| NCT05139225 |
Memorial Sloan Kettering Cancer Center |
TTI-622 |
anti-CD47 |
relapsed/refractory multiple myeloma |
TTI-662 + Daratumumab |
I |
Ongoing |